Keywords: jazz/ucb, drug, meets, endpoints, ph, iii, trial

Jazz/UCB drug meets endpoints in Ph III trial

Article | 01 December 2008

Print This

US firm Jazz Pharmaceuticals and Belgium's UCB have reported that the first of two pivotal trials of sodium oxybate for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in